174 related articles for article (PubMed ID: 27701875)
1. Possible role of aprepitant for intractable nausea and vomiting following whole brain radiotherapy-a case report.
Ahuja D; Bharati SJ; Gupta N; Kumar R; Bhatnagar S
Ann Palliat Med; 2016 Oct; 5(4):315-318. PubMed ID: 27701875
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Ades S; Halyard M; Wilson K; Ashikaga T; Heimann R; Kumar S; Blackstock W
Support Care Cancer; 2017 May; 25(5):1503-1510. PubMed ID: 28032216
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
5. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
6. Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
McKenzie E; Chan D; Parsafar S; Razvi Y; McFarlane T; Rico V; Pasetka M; DeAngelis C; Chow E
Support Care Cancer; 2019 Sep; 27(9):3245-3252. PubMed ID: 31119459
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Rowbottom L; Pasetka M; McDonald R; Hunyh L; Raman S; DeAngelis C; Chow E
Ann Palliat Med; 2015 Jan; 4(1):32-4. PubMed ID: 25813417
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
9. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
10. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
11. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
12. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Li WS; van der Velden JM; Ganesh V; Vuong S; Raman S; Popovic M; Lam H; Wong KH; Ngan RK; Burbach JPM; DeAngelis C; Xxxx RM; Chow E
Ann Palliat Med; 2017 Apr; 6(2):104-117. PubMed ID: 28249542
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Moore S; Tumeh J; Wojtanowski S; Flowers C
Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
[TBL] [Abstract][Full Text] [Related]
19. Latest advances in the management of radiation-induced pain flare, nausea and vomiting.
Chiu N; Chiu L; Popovic M; DeAngelis C; Pasetka M; Lutz S; Zhang N; Marta GN; Mendez LC; Lechner B; Pulenzas N; Milakovic M; Chow R; Chow E
Ann Palliat Med; 2016 Jan; 5(1):50-7. PubMed ID: 26841815
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]